Limited Time Offer
Get $1000 towards your
first investment
Start investing in private markets with Linqto – your access to disruptive startups and pre-IPO companies.
*Terms and conditions apply. See details
Cheetah Medical, founded in 2000 and headquartered in Newton Center, Massachusetts, is a leading provider of non-invasive cardiac output and hemodynamic monitoring solutions. The company specializes in developing and commercializing accurate, non-invasive monitoring systems for critically ill patients. Their flagship product, the NICOM Noninvasive Hemodynamic Monitoring System, utilizes proprietary BIOREACTANCE technology.
Since its inception, Cheetah Medical has raised a total of $109.26 million in funding, demonstrating investor confidence in its innovative medical technology. The company's focus on non-invasive monitoring solutions positions it well in the growing healthcare technology sector.
On September 10, 2019, Cheetah Medical was acquired by Baxter for a reported amount between $190 million and $230 million. This acquisition marks a significant milestone in the company's history and reflects the value of its technology in the medical device industry.
Given the acquisition by Baxter, it is unlikely that Cheetah Medical will pursue an initial public offering (IPO) as an independent entity. The company's future growth and development will likely be integrated into Baxter's broader strategic plans. Investors interested in gaining exposure to Cheetah Medical's technology and market potential may consider exploring investment opportunities in Baxter, its parent company.
Get $1000 towards your
first investment
*Terms and conditions apply. See details
While Cheetah Medical's IPO prospects remain uncertain, investors interested in innovative medical technology companies don't have to wait. At Linqto, we offer members access to interests in promising pre-IPO private companies, including potential leaders in the healthcare and medical device sectors. Our platform allows you to diversify your portfolio with lower minimum investments, potentially benefiting from the growth of emerging medical technology firms before they go public.
*These comments should not be interpreted to mean that the company is formally pursuing or foregoing an IPO. The information provided above is based on current online discussions and is not intended as investment advice. Linqto does not endorse or guarantee the accuracy of this information, and we strongly recommend conducting your own research or consulting with a professional advisor before making any investment decisions. Linqto cannot be held liable for any investment outcomes resulting from the use of this information.
